NeuroSense Therapeutics Ltd.
NRSN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $22,322 | $10,707 | $14,036 | $26,706 |
| - Cash | $3,378 | $2,640 | $3,543 | $11,063 |
| + Debt | $73 | $142 | $211 | $1,828 |
| Enterprise Value | $19,017 | $8,209 | $10,704 | $17,471 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$22 | -$97 | -$89 | -$3 |
| % Margin | – | – | – | – |
| EBITDA | -$9,877 | -$9,638 | -$12,229 | -$2,884 |
| % Margin | – | – | – | – |
| Net Income | -$10,210 | -$10,107 | -$12,340 | -$4,041 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.55 | -0.83 | -1.07 | -0.23 |
| % Growth | 33.7% | 22.4% | -365.2% | – |
| Operating Cash Flow | -$10,135 | -$8,354 | -$7,586 | -$1,539 |
| Capital Expenditures | -$3 | -$29 | -$70 | -$17 |
| Free Cash Flow | -$10,138 | -$8,383 | -$7,656 | -$1,556 |